Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

1.4K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
1.4K
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

412
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
412
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

504
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
504
Sleepwalking and Sleep Talking01:17

Sleepwalking and Sleep Talking

343
Somnambulism, commonly known as sleepwalking, involves individuals engaging in activities ranging from simple walking to more complex behaviors such as driving. Sleepwalking typically occurs during the slow-wave sleep stages 3 and 4 early in the night when the person is not dreaming, contradicting the myth that sleepwalkers are acting out their dreams.
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...
343
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

255
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
255
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

325
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
325

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postmortem distribution of mitragynine and 7-hydroxymitragynine in 51 cases.

Journal of analytical toxicology·2025
Same author

1,1-Difluoroethane Forensic Aspects for the Toxicologist and Pathologist.

Journal of analytical toxicology·2021
Same author

Fentanyl and Driving Impairment.

Journal of analytical toxicology·2020
Same author

Driving Impairment Cases Involving Etizolam and Flubromazolam.

Journal of analytical toxicology·2020
Same author

U-47700: A Not So New Opioid.

Journal of analytical toxicology·2017
Same author

Roadside drug testing: An evaluation of the Alere DDS<sup>®</sup> 2 mobile test system.

Drug testing and analysis·2017
Same journal

Theory put into practice: probabilistic approach to propranolol as the cause of death.

Journal of analytical toxicology·2026
Same journal

Is drug facilitated sexual assault changing? About a case involving 4-bromomethcathinone.

Journal of analytical toxicology·2026
Same journal

Differentiation of 2-, 3-, and 4-Fluorofuranylfentanyl Using HPLC-MS and Human Liver Microsomes.

Journal of analytical toxicology·2026
Same journal

Trends and Circumstances of Pediatric Fentanyl Deaths in North Carolina: A 10-year Retrospective Study.

Journal of analytical toxicology·2026
Same journal

Drug Detection in Traffic-Related Fatalities in Connecticut (2020-2024).

Journal of analytical toxicology·2026
Same journal

Characterization of postmortem γ-hydroxybutyric acid (GHB) and a novel model to discern exogenous use.

Journal of analytical toxicology·2026
See all related articles

Related Experiment Video

Updated: Sep 27, 2025

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects
11:12

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects

Published on: September 18, 2012

17.5K

Driving Impairment Cases Involving Flualprazolam.

Kimberly B Youso1, Kei A Osawa1, Marina L Divine1

  • 1Sedgwick County Regional Forensic Science Center, 1109 N. Minneapolis St., Wichita, KS 67214, USA.

Journal of Analytical Toxicology
|April 11, 2022
PubMed
Summary
This summary is machine-generated.

Flualprazolam, a novel psychoactive substance, was detected in 19 impaired driving cases, highlighting the need for vigilant laboratory testing of emerging benzodiazepines.

More Related Videos

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.1K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K

Related Experiment Videos

Last Updated: Sep 27, 2025

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects
11:12

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects

Published on: September 18, 2012

17.5K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.1K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K

Area of Science:

  • Forensic Toxicology
  • Pharmacology

Background:

  • Flualprazolam is an emerging novel psychoactive substance (NPS) within the benzodiazepine class.
  • Increasing prevalence of flualprazolam necessitates updated toxicological screening protocols.

Purpose of the Study:

  • To report the detection of flualprazolam in drivers suspected of impaired driving.
  • To characterize blood concentrations of flualprazolam in this population.

Main Methods:

  • Analysis of blood samples from 19 drivers stopped for impaired driving between July 2019 and May 2020.
  • Toxicology laboratory at Sedgwick County Regional Forensic Science Center.

Main Results:

  • Flualprazolam was detected in approximately 9% of total toxicology cases during the study period.
  • Detected blood concentrations ranged from 4 to 69 ng/mL, with a mean of 20.9 ng/mL and median of 15 ng/mL.

Conclusions:

  • The rising detection rates of flualprazolam underscore its growing presence in impaired driving incidents.
  • Laboratories must maintain vigilance in testing for NPS like flualprazolam due to their pharmacological potency at low concentrations.